EP0045661A1 - Pharmaceutical compositions comprising prostaglandins - Google Patents
Pharmaceutical compositions comprising prostaglandins Download PDFInfo
- Publication number
- EP0045661A1 EP0045661A1 EP81303564A EP81303564A EP0045661A1 EP 0045661 A1 EP0045661 A1 EP 0045661A1 EP 81303564 A EP81303564 A EP 81303564A EP 81303564 A EP81303564 A EP 81303564A EP 0045661 A1 EP0045661 A1 EP 0045661A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pgf
- monkeys
- prostaglandin
- prostaglandins
- trinor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 title description 19
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 210000004914 menses Anatomy 0.000 claims abstract description 14
- 241000288906 Primates Species 0.000 claims abstract description 13
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims abstract description 9
- 150000001408 amides Chemical class 0.000 claims abstract description 6
- 150000004702 methyl esters Chemical class 0.000 claims description 10
- WMLGLMGSFIXSGO-KTXJXPLISA-N 9-Deoxy-9-methylene-16,16-dimethyl -PGE2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(O)=O WMLGLMGSFIXSGO-KTXJXPLISA-N 0.000 claims description 9
- 150000001768 cations Chemical class 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 abstract description 5
- 150000002148 esters Chemical class 0.000 abstract 2
- 241000282693 Cercopithecidae Species 0.000 description 30
- 230000035935 pregnancy Effects 0.000 description 20
- -1 prostaglandin compounds Chemical class 0.000 description 17
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 230000027758 ovulation cycle Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 125000005907 alkyl ester group Chemical group 0.000 description 7
- 210000004246 corpus luteum Anatomy 0.000 description 7
- 230000003529 luteolytic effect Effects 0.000 description 7
- 229960003387 progesterone Drugs 0.000 description 7
- 239000000186 progesterone Substances 0.000 description 7
- 241000282560 Macaca mulatta Species 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 239000000130 luteolytic agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- QFUSOYKIDBRREL-NSCUHMNNSA-N (e)-but-2-en-1-amine Chemical compound C\C=C\CN QFUSOYKIDBRREL-NSCUHMNNSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- LJDSTRZHPWMDPG-UHFFFAOYSA-N 2-(butylamino)ethanol Chemical compound CCCCNCCO LJDSTRZHPWMDPG-UHFFFAOYSA-N 0.000 description 1
- NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
- RAQDKJJAUOPRQM-UHFFFAOYSA-N 2-[n-(2-hydroxyethyl)-4-(2-methylbutan-2-yl)anilino]ethanol Chemical compound CCC(C)(C)C1=CC=C(N(CCO)CCO)C=C1 RAQDKJJAUOPRQM-UHFFFAOYSA-N 0.000 description 1
- IOAOAKDONABGPZ-UHFFFAOYSA-N 2-amino-2-ethylpropane-1,3-diol Chemical compound CCC(N)(CO)CO IOAOAKDONABGPZ-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 1
- RGHPCLZJAFCTIK-UHFFFAOYSA-N 2-methylpyrrolidine Chemical compound CC1CCCN1 RGHPCLZJAFCTIK-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-UHFFFAOYSA-N 6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNCC(O)C(O)C(O)C(O)CO MBBZMMPHUWSWHV-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- AKNUHUCEWALCOI-UHFFFAOYSA-N N-ethyldiethanolamine Chemical compound OCCN(CC)CCO AKNUHUCEWALCOI-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- UTLCNJREJFJDLH-YNNPMVKQSA-N PGF2alpha-1,15-lactone Chemical compound C/1=C\[C@H](CCCCC)OC(=O)CCC\C=C/C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2\1 UTLCNJREJFJDLH-YNNPMVKQSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- YOUGRGFIHBUKRS-UHFFFAOYSA-N benzyl(trimethyl)azanium Chemical compound C[N+](C)(C)CC1=CC=CC=C1 YOUGRGFIHBUKRS-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 230000029860 luteolysis Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XJINZNWPEQMMBV-UHFFFAOYSA-N n-methylhexan-1-amine Chemical compound CCCCCCNC XJINZNWPEQMMBV-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- JJPVWQWOOQYHCB-UHFFFAOYSA-N triethyl(phenyl)azanium Chemical compound CC[N+](CC)(CC)C1=CC=CC=C1 JJPVWQWOOQYHCB-UHFFFAOYSA-N 0.000 description 1
- RKBCYCFRFCNLTO-UHFFFAOYSA-N triisopropylamine Chemical compound CC(C)N(C(C)C)C(C)C RKBCYCFRFCNLTO-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- compositions comprising a combination of prostaglandin compounds which may act synergically to induce menses and interupt early pregnancy in female primates, particularly humans.
- Prostaglandin compounds of the F series have been disclosed as being useful in stimulating smooth muscle, inhibiting gastric secretion, decongesting nasal passages, decreasing blood platelet adhesion, and for a wide variety of purposes in reproductive medicine, e.g. labour induction, abortion, cervical dilation, regulation of estrus and regulation of the menstrual cycle.
- Prostaglandin compounds of the E series have been disclosed as being useful in stimulating smooth muscle, affecting lipolytic activity, inhibiting gastric secretion, controlling spasms and facilitating breathing in asthmatic conditions, decongesting nasal passages; decreasing blood platelet adhesion, and for a wide variety of uses in reproductive medicine, e.g. labour induction, abortion, cervical dilation, regulation of the estrus and regulation of the menstrual cycle.
- a problem associated with known prostaglandin compositions for luteolysis is the acute toxicity of some of the prostaglandins.
- 16,16-dimethyl-PGE 2 is part of the most potent luteolytic combination disclosed in US Patent Specification No. 2,978,229.
- the other prostaglandin is 15(S), 16(R)-dimethyl-PGF 2 ⁇ .
- the "synergic"combination employed in the rat included 250 ug/kg body weight of 16,16-dimethyl PGE2 which is very toxic in primates, causing convulsions and death at doses as low as 100 ⁇ g/kg body weight.
- Known prostaglandins of the E and F series include 5-oxa-17-phenyl-18,19,20-trinor-PGF 1 ⁇ and its alkyl esters, which are disclosed in US Patent Specification No. 3,864,387.
- 9-Deoxy-16,16-dimethyl-9-methylene-PGE 2 is disclosed in US Patent Specification No. 4,165,436.
- PGF 2 ⁇ 1,15-lactone is disclosed in US Patent Specification No. 4,045,449.
- 5-Oxa-17-phenyl-18,19,20-trinor-PGF 1 ⁇ amide is disclosed in U.S. Patent Specification No. 4,081,478.
- a composition comprises a first prostaglandin, of the formula wherein R 10 is NH 2 , OH, C 1-12 alkoxy or OM and M is a pharmacologically acceptable cation, and a second prostaglandin which is PGF 2 ⁇ , 1,15-lactone or is of the formula wherein R 20 is hydrogen, C 1-12 alkyl or a pharmacologically acceptable cation.
- the first prostaglandin is the acid form, amide, alkyl ester or salt of 5-oxa-17-phenyl-18,19,20-trinor-PGF 1 ⁇ .
- the second prostaglandin is the acid form, or an alkyl ester or a salt, of 9-deoxo-16,16-dimethyl-9-methylene-PGE 2 , or PGF 2 ⁇ , 1,15-lactone.
- alkyl ester of the first or second prostaglandin ' may be a methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl or dodecyl ester, or any isomeric form thereof.
- a composition of the present invention may be administered to a female primate, and is of particular value when administered to a female human, at any point in time during the reproductive cycle, starting from ovulation and continuing through the first trimester of pregnancy, to inhibit pregnancy and cause menstruation.
- a composition of this invention is advantageously used in early pregnancy, when menses is delayed, or prior to the occurrence of menses.
- a composition of the present invention is preferably.administered up to the eighth week of pregnancy, to inhibit corpus luteum function and, effectively, terminate pregnancy, just prior to expected menstruation, or when menstruation is delayed by up to 90 days. Such a composition is often less efficacious in late pregnancy, particularly in the third trimester.
- the effective total dosage of the first and second prostaglandins depends on the route of administration. When administered intramuscularly, the effective total dosage is generally from 0.1 to 50 mg/kg body weight. Equivalent dosages may be employed for alternative routes of administration.
- the "total dosage” refers to the total amount of the first and second prostaglandins employed to achieve the desired result. This total dosage may be administered all at once, e.g. as a single injection, or over a short time period, e.g. by injection every eight hours for several days.
- the weight ratio of the first and second prostaglandins in a composition of the invention is usually dependent on the particular prostaglandins. As for the total dosage, this factor may be determined by a skilled physician.
- the weight ratio of the PGF 1 ⁇ compound to the PGE 2 compound is preferably from 2:1 to 20:1.
- the weight ratio of the PGF 1 ⁇ compound to the lactone compound is preferably from 2:1 to 5:1.
- the weight ratio of the amide to the PGE 2 compound is preferably from 5:1 to 30:1.
- a composition of the invention may be in the form of a pharmaceutical composition comprising, in addition to the first and second prostaglandins, a physiologically acceptable excipient.
- the composition may be in a sterile form, suitable for intravenous infusion or subcutaneous or intramuscular injection.
- Other routes of administration for which the compositions may suitably be prepared are nasal, oral, buccal, intravaginal, intracervical, intrauterine and rectal.
- the compositions may be formulated into slow-release vehicles or polymers, such as silicone rubber, to form devices for subcutaneous, intravaginal, intracervical or intrauterine administration.
- compositions of the invention may provide results superior to the administration of one of the prostaglandins administered individually. It is of course highly desirable that a menses-inducing agent should be 100% effective. It is possible to formulate a composition of the invention which can provide 100% pregnancy inhibition at a lower dosage than is required for either prostaglandin administered individually.
- compositions of the present invention can involve significantly increases the safety of their use. Side effects, such as nausea, fever and diarrhoea, can be decreased. By comparison with prostaglandins of the E series which are known for their thermogenic effect at dosages employed for menses induction, such effects can be avoided by using the combination compositions of the present invention.
- a problem associated with finding menses-inducing agents for primates, including humans, is that agents which exhibit good luteolytic activity in rodents such as rats and hamsters, are frequently ineffective in inducing menses in primates.
- 9-deoxo-16,16-dimethyl-9-methylene-PGE 2 by itself is not very effective as an antifertility agent in hamsters, but is very effective in combination with 5-oxa-17-phenyl-18,19,20-trinor-PGF 1 ⁇ , methyl ester for menses induction, as seen by the example below.
- Pharmacologically acceptable salts of the formulas IV and V compounds useful for the purposes described above are those with pharmacologically acceptable metal cations, ammonium, amine cations, or quaternary ammonium cations.
- Especially preferred metal cations are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron are within the scope of this invention.
- amine cations are those derived from primary, secondary, or tertiary amines.
- suitable amines are methylamine, dimethylamine, trimethylamine, ethylamine, dibutylamine, triisopropylamine, N-methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, ⁇ -phenylethylamine, ⁇ -phenylethylamine, ethylenediamine, diethylenetriamine, and like aliphatic, cycloaliphatic and araliphatic amines containing up to and including about 18 carbon atoms, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereof, e.g., 1-methylpiperidine
- Suitable pharmacologically acceptable quaternary ammonium cations are tetramethylammonium, tetraethylammonium, benzyltrimethylammonium and phenyltriethylammonium.
- mCG monkey chorionic gonadotropin
- Pregnancy was confirmed in all monkeys prior to treatment by the qualitative determination of mCG in the serum. Treatments were given by intramuscular injection at 7:00 a.m., 3:00 p.m. and 11:00 p.m. of day 28 from the previous menses. Prostaglandins were given as an emulsion in I ml of 4% glass-distilled ethanol and 96% sterile aqueous vehicle, containing 10 mg of carboxymethylcellulose, 4 mg of polysorbate 80, and 0.42 mg of propyl- paraben per milliter.
- Example 1 The procedure of Example 1 was followed exactly using another three monkeys, except that no S-oxa-17-phenyl-18,19,20-trinor-PGF la , methyl ester was administered. Pregnancy terminated in one of these monkeys, after a delay of 4 weeks from treatment.
- Example l Following the procedure of Example l,three pregnant rhesus monkeys were given a single injection of 7.5 mg of 5-oxa-17-phenyl-18,19,20-trinor-PGF 1 ⁇ , methyl ester and 0.5 mg of 9-deoxo-16,16-dimethyl-9-methylene-PGE 2 at 7:00 a.m. on day 28 of the menstrual cycle. Pro-. gesterone and mCG dropped to 10% of pretreatment levels within 24 hours of injection.' Pregnancy terminated promptly in all three monkeys; menstrual bleeding was first observed on the day of treatment, the day after treatment, and 8 days after treatment, respectively for the three monkeys. No side-effects were observed in any of the monkeys.
- Example 2 Using the procedure of Example 1, three rhesus monkeys were given three doses of 5 mg of 5-oxa-17-phenyl-18,19,20-trinor-PGF 1 ⁇ , methyl ester and 1 mg of PGF 2 ⁇ ,1,15-lactone. The prostaglandins were mixed together in the same vehicle and given at the same injection site.
- Serum progesterone declined below 1 ng/ml within 24 hours of initial treatment and remained depressed throughout the study. Serum progesterone declined to 75% of normal in the other two treated monkeys within 24 hours of initial treatment, but rebounded to normal despite continued treatment.
- Example 2 Following the procedure of Example 1, nine 7.5 mg injections of 5-oxa-17-phenyl-18,19,20-trinor-PGF 1 ⁇ , methyl ester were administered to each of two pregnant monkeys. The total dosage was 67.5 mg per monkey. Pregnancy terminated in one monkey. The monkeys experienced slight appetite depression on the days of treatment.
- Example 2 Following the procedure of Example 1, three injections, each containing 7.5 mg of 5-oxa-17-pheny-18,19,20-trinor-PGF 1 ⁇ , amide and 0.5 mg of 9-deoxy-9-methylene-16,16-dimethyl-PGE 2 , were administered to two pregnant rhesus monkeys, in eight hour intervals on day 28 of the menstrual cycle. Pregnancy terminated in both monkeys.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This invention relates to compositions comprising a combination of prostaglandin compounds which may act synergically to induce menses and interupt early pregnancy in female primates, particularly humans.
- Prostaglandin compounds of the F series have been disclosed as being useful in stimulating smooth muscle, inhibiting gastric secretion, decongesting nasal passages, decreasing blood platelet adhesion, and for a wide variety of purposes in reproductive medicine, e.g. labour induction, abortion, cervical dilation, regulation of estrus and regulation of the menstrual cycle. Prostaglandin compounds of the E series have been disclosed as being useful in stimulating smooth muscle, affecting lipolytic activity, inhibiting gastric secretion, controlling spasms and facilitating breathing in asthmatic conditions, decongesting nasal passages; decreasing blood platelet adhesion, and for a wide variety of uses in reproductive medicine, e.g. labour induction, abortion, cervical dilation, regulation of the estrus and regulation of the menstrual cycle.
- While a number of prostaglandins have been shown to be effective as luteolytic agents in various animal tests, it is difficult to find a prostaglandin which is 100% effective in inducing menses in female primates but which exhibits little or no toxicity or side effects. "Luteolytic" agents are those which cause corpus luteum regression. A functional corpus luteum is essential in early pregnancy.
- Ithas been demonstrated that combinations of certain prostaglandins of the F and E series are effective in inhibiting nidation (implantation of the ovum) in rats and hamsters, as disclosed in US Patent Specification No. 3,978,229. However, such disclosures are of limited value in assessing the existence of primate luteolytic activity, since it is not possible to predict accurately the luteolytic activity of a prostaglandin combination in primates using rodent data. See, for example, "The Use of PG's in Human Reproduction", Population Reports, Population Information Program, The Johns Hopkins University, Prostaglandins, Series G, No. 8 (March 1980); and J.W. Wilks, "A Procedure for Evaluating Luteolytic Agents in Primates", Ovarian Follicular and Corpus Luteum Function, C.P. Channing et al., Eds., pp. 757-766 (Plenum Press, New York 1979).
- Various control mechanisms exist governing corpus luteum function in mammalian species. The uterus apparently regulates corpus luteum function in infraprimate animals, but the role of the uterus in primate luteal function has not been established. Thus, while PGF2a, a physiological luteolytic substance of uterine origin, has been successfully employed to regulate estrous cycles of domestic animals, J.W. Lauderdale et al., J. Anim. Sci. 38:964 (1974), it is ineffective in controlling the human corpus luteum, W.J. LeMaire et al,Prostaglandins 1:259 (1972).
- An effective luteolytic method of inducing menses in females must be able to counteract the corpus luteum-stimulating effects of chorionic gonadotropin. Agents which have been shown to be effective during non- fertile mestrual cycles have been ineffective during early gestation and in non-pregnant women given exogenous human chorionic gonadotropin (hCG). See, for example, J.W. Wilks, supra, and references cited therein.
- A problem associated with known prostaglandin compositions for luteolysis is the acute toxicity of some of the prostaglandins. For example, 16,16-dimethyl-PGE2 is part of the most potent luteolytic combination disclosed in US Patent Specification No. 2,978,229. The other prostaglandin is 15(S), 16(R)-dimethyl-PGF2α. However, the "synergic"combination employed in the rat included 250 ug/kg body weight of 16,16-dimethyl PGE2 which is very toxic in primates, causing convulsions and death at doses as low as 100 µg/kg body weight.
- Known prostaglandins of the E and F series include 5-oxa-17-phenyl-18,19,20-trinor-PGF1α and its alkyl esters, which are disclosed in US Patent Specification No. 3,864,387. 9-Deoxy-16,16-dimethyl-9-methylene-PGE2 is disclosed in US Patent Specification No. 4,165,436. PGF2α 1,15-lactone is disclosed in US Patent Specification No. 4,045,449. 5-Oxa-17-phenyl-18,19,20-trinor-PGF1α amide is disclosed in U.S. Patent Specification No. 4,081,478.
- According to the present invention, a composition comprises a first prostaglandin, of the formula
- The first prostaglandin is the acid form, amide, alkyl ester or salt of 5-oxa-17-phenyl-18,19,20-trinor-PGF1α. The second prostaglandin is the acid form, or an alkyl ester or a salt, of 9-deoxo-16,16-dimethyl-9-methylene-PGE2, or PGF2α, 1,15-lactone.
- If an alkyl ester of the first or second prostaglandin ' is used, this may be a methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl or dodecyl ester, or any isomeric form thereof.
- A composition of the present invention may be administered to a female primate, and is of particular value when administered to a female human, at any point in time during the reproductive cycle, starting from ovulation and continuing through the first trimester of pregnancy, to inhibit pregnancy and cause menstruation. A composition of this invention is advantageously used in early pregnancy, when menses is delayed, or prior to the occurrence of menses. A composition of the present invention is preferably.administered up to the eighth week of pregnancy, to inhibit corpus luteum function and, effectively, terminate pregnancy, just prior to expected menstruation, or when menstruation is delayed by up to 90 days. Such a composition is often less efficacious in late pregnancy, particularly in the third trimester.
- The effective total dosage of the first and second prostaglandins depends on the route of administration. When administered intramuscularly, the effective total dosage is generally from 0.1 to 50 mg/kg body weight. Equivalent dosages may be employed for alternative routes of administration. The "total dosage" refers to the total amount of the first and second prostaglandins employed to achieve the desired result. This total dosage may be administered all at once, e.g. as a single injection, or over a short time period, e.g. by injection every eight hours for several days.
- The weight ratio of the first and second prostaglandins in a composition of the invention is usually dependent on the particular prostaglandins. As for the total dosage, this factor may be determined by a skilled physician.
- When 5-oxa-17-phenyl-17,19,20-trinor-PGF1α, or an alkyl ester thereof, and 9-deoxo-16,16-dimethyl-9-methylene-PGE2, or an alkyl ester thereof, are employed, the weight ratio of the PGF1α compound to the PGE2 compound is preferably from 2:1 to 20:1. When PGF2a, 1,15-lactone is employed, the weight ratio of the PGF1α compound to the lactone compound is preferably from 2:1 to 5:1. When the first prostaglandin is 5-oxa-17-phenyl-18,19,20-trinor-PGF1α, amide and the second 9-deoxo-16,16-dimethyl-9-methylene-PGE2, or an alkyl ester thereof, the weight ratio of the amide to the PGE2 compound is preferably from 5:1 to 30:1.
- A composition of the invention may be in the form of a pharmaceutical composition comprising, in addition to the first and second prostaglandins, a physiologically acceptable excipient. The composition may be in a sterile form, suitable for intravenous infusion or subcutaneous or intramuscular injection. Other routes of administration for which the compositions may suitably be prepared are nasal, oral, buccal, intravaginal, intracervical, intrauterine and rectal. The compositions may be formulated into slow-release vehicles or polymers, such as silicone rubber, to form devices for subcutaneous, intravaginal, intracervical or intrauterine administration.
- The use of a novel composition may provide results superior to the administration of one of the prostaglandins administered individually. It is of course highly desirable that a menses-inducing agent should be 100% effective. It is possible to formulate a composition of the invention which can provide 100% pregnancy inhibition at a lower dosage than is required for either prostaglandin administered individually.
- The lower dosages which the compositions of the present invention can involve significantly increases the safety of their use. Side effects, such as nausea, fever and diarrhoea, can be decreased. By comparison with prostaglandins of the E series which are known for their thermogenic effect at dosages employed for menses induction, such effects can be avoided by using the combination compositions of the present invention.
- As is noted above, a problem associated with finding menses-inducing agents for primates, including humans, is that agents which exhibit good luteolytic activity in rodents such as rats and hamsters, are frequently ineffective in inducing menses in primates.
- Thus, 9-deoxo-16,16-dimethyl-9-methylene-PGE2 by itself is not very effective as an antifertility agent in hamsters, but is very effective in combination with 5-oxa-17-phenyl-18,19,20-trinor-PGF1α, methyl ester for menses induction, as seen by the example below.
- While all of the combinations disclosed herein are virtually 100% effective in inhibiting pregnancy in primates at the effective dose, the combination using 5-oxa-17-phenyl-18,19,20-trinor-PGF1α, methyl ester and 9-deoxo-16,16-dimethyl-9-methylene-PGE2 is most preferred.
- Pharmacologically acceptable salts of the formulas IV and V compounds useful for the purposes described above are those with pharmacologically acceptable metal cations, ammonium, amine cations, or quaternary ammonium cations.
- Especially preferred metal cations are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron are within the scope of this invention.
- Pharmacologically acceptable amine cations are those derived from primary, secondary, or tertiary amines. Examples of suitable amines are methylamine, dimethylamine, trimethylamine, ethylamine, dibutylamine, triisopropylamine, N-methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, α-phenylethylamine, β-phenylethylamine, ethylenediamine, diethylenetriamine, and like aliphatic, cycloaliphatic and araliphatic amines containing up to and including about 18 carbon atoms, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereof, e.g., 1-methylpiperidine, 4-ethylmorpholine, 1-isopropylpyrroldine, 2-methylpyrrolidine, 1,4-dimethylpiperazine, 2-methylpiperidine, and the like, as well as amines containing water-solubilizing or hydrophilic groups, e.g., mono-, di-, and triethanolamine, ethyldiethanolamine, N-butylethanolamine, 2-amino-l-butanol, 2-amino-2-ethyl-1,3-propanediol , 2-amino-2-methyl-1-propanol, tris (hydroxymethyl) aminomethane, N-(p-tert-amylphenyl)diethanolamine, galactamine, N-methyl- glycamine, N-methylglucosamine, ephedrine, phenylephrine, epinephrine, procaine, and the like.
- Examples of suitable pharmacologically acceptable quaternary ammonium cations are tetramethylammonium, tetraethylammonium, benzyltrimethylammonium and phenyltriethylammonium.
- The invention is illustrated by the following Examples. Reference Examples are also given.
- Three female rhesus monkeys were placed with males from days 11 through 15 of the menstrual cycle. 5 ml blood samples were collected daily between 7 and 9:00 a.m. beginning on day 20 of the menstrual cycle and continued until day 36 from the previous menses. Concentrations of monkey chorionic gonadotropin (mCG) and progesterone were determined for each blood sample by radioimmunoassay.
- Pregnancy was confirmed in all monkeys prior to treatment by the qualitative determination of mCG in the serum. Treatments were given by intramuscular injection at 7:00 a.m., 3:00 p.m. and 11:00 p.m. of day 28 from the previous menses. Prostaglandins were given as an emulsion in I ml of 4% glass-distilled ethanol and 96% sterile aqueous vehicle, containing 10 mg of carboxymethylcellulose, 4 mg of polysorbate 80, and 0.42 mg of propyl- paraben per milliter. 75 mg of 5-oxa-17-phenyl-18,19,20- trinor-PGF1α, methyl ester and 0.5 mg of 9-deoxo-16,16-dimethyl-9-methylene-PGE2 were administered at each injection. The prostaglandins were mixed together in the same vehicle and given at the same injection site.
- Pregnancy terminated promptly in the three monkeys given the combination of prostaglandins. Vaginal bleeding commenced on the day after treatment in two of these monkeys, and vaginal bleeding began on the second day following prostaglandin administration in the third monkey.
- Serum progesterone and mCG declined to 10% of pretreatment values within 24 hours of initial treatment. Progesterone remained depressed throughout the study, and mCG disappeared from the blood.
- Slight anorexia was observed in one of the monkeys on the day of treatment.
- The procedure of Example 1 was followed exactly using another three monkeys, except that no S-oxa-17-phenyl-18,19,20-trinor-PGFla, methyl ester was administered. Pregnancy terminated in one of these monkeys, after a delay of 4 weeks from treatment.
- Following the procedure of Example l,three pregnant rhesus monkeys were given a single injection of 7.5 mg of 5-oxa-17-phenyl-18,19,20-trinor-PGF1α, methyl ester and 0.5 mg of 9-deoxo-16,16-dimethyl-9-methylene-PGE2 at 7:00 a.m. on day 28 of the menstrual cycle. Pro-. gesterone and mCG dropped to 10% of pretreatment levels within 24 hours of injection.' Pregnancy terminated promptly in all three monkeys; menstrual bleeding was first observed on the day of treatment, the day after treatment, and 8 days after treatment, respectively for the three monkeys. No side-effects were observed in any of the monkeys.
- Using the procedure of Example 1, three rhesus monkeys were given three doses of 5 mg of 5-oxa-17-phenyl-18,19,20-trinor-PGF1α, methyl ester and 1 mg of PGF2α,1,15-lactone. The prostaglandins were mixed together in the same vehicle and given at the same injection site.
- Pregnancy terminated in all three monkeys, promptly in two. For these monkeys, progesterone and mCG declined markedly within 24 hours of treatment and remained depressed throughout the study. Serum progesterone and mCG declined in the third monkey and remained depressed throughout the study. This monkey was no longer pregnant 18 days after blood sampling was completed.
- Slight appetite depression was observed on the day of treatment of all three monkeys. The animals ate approximately two-thirds of the food provided for them, but no other side-effects were seen.
- Following the procedure of Example 1, 7.5 mg of 5-oxa-17-phenyl-18,19,20-trinor-PGFla, methyl ester in one ml of sterile vehicle, were injected on days 28 and 29 of the menstrual cycle to each of two monkeys, and on days 27 and 28 for one monkey, at 7:00 a.m. and 7:00 p.m. Another 3 monkeys were injected with sterile vehicle only, following the same regimen, on days 28 and 29.
- Pregnancy terminated in one of the monkeys receiving the prostaglandin compound. Serum progesterone declined below 1 ng/ml within 24 hours of initial treatment and remained depressed throughout the study. Serum progesterone declined to 75% of normal in the other two treated monkeys within 24 hours of initial treatment, but rebounded to normal despite continued treatment.
- Slight diarrhoea was observed in two of the treated monkeys. None of the three ate their food on days of treatment.
- Following the procedure of Example 1, nine 7.5 mg injections of 5-oxa-17-phenyl-18,19,20-trinor-PGF1α, methyl ester were administered to each of two pregnant monkeys. The total dosage was 67.5 mg per monkey. Pregnancy terminated in one monkey. The monkeys experienced slight appetite depression on the days of treatment.
- Using the procedure of Reference Example B, two injections of PGF2α, 1,15-lactone were given on day 28 of the menstrual cycle in 3 mg portions to each of three female monkeys. Pregnancy was terminated in one of the three animals.
- Nine female rhesus monkeys of proven fertility were caged with male rhesus monkeys of proven fertility from days 11 through 15 of the menstrual cycle. The female monkeys received intramuscular injections of 1.5 mg of 5-oxa-17-phenyl-18,19,20-trinor-PGF1α, methyl ester and 0.1 mg of 9-deoxo-16,16-dimethyl-9-methylene-PGF2 once daily on days 18 through 22 of the menstrual cycle. The prostaglandins were mixed together in the same vehicle and given at the same injection site. None of the monkeys treated with the combination became pregnant.
- Following the procedure of Example 1, three injections, each containing 7.5 mg of 5-oxa-17-pheny-18,19,20-trinor-PGF1α, amide and 0.5 mg of 9-deoxy-9-methylene-16,16-dimethyl-PGE2, were administered to two pregnant rhesus monkeys, in eight hour intervals on day 28 of the menstrual cycle. Pregnancy terminated in both monkeys.
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/175,467 US4289785A (en) | 1980-08-06 | 1980-08-06 | Method and compositions involving prostaglandins |
US175467 | 1980-08-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0045661A1 true EP0045661A1 (en) | 1982-02-10 |
EP0045661B1 EP0045661B1 (en) | 1983-10-12 |
Family
ID=22640329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP81303564A Expired EP0045661B1 (en) | 1980-08-06 | 1981-08-05 | Pharmaceutical compositions comprising prostaglandins |
Country Status (4)
Country | Link |
---|---|
US (1) | US4289785A (en) |
EP (1) | EP0045661B1 (en) |
JP (1) | JPS5754119A (en) |
DE (1) | DE3161182D1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0097439A2 (en) * | 1982-06-18 | 1984-01-04 | The Upjohn Company | A crystalline prostaglandin salt |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993008804A1 (en) * | 1991-11-08 | 1993-05-13 | Kyoto Pharmaceutical Industries, Ltd. | Pharmaceutical preparation containing prostaglandin compound for rectal or vaginal administration |
US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US20070191320A1 (en) * | 1998-12-10 | 2007-08-16 | Nexmed Holdings, Inc. | Methods of treatment for female sexual arousal disorder |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3978229A (en) * | 1974-04-11 | 1976-08-31 | Ono Pharmaceutical Co., Ltd. | Synergistic composition comprising PGF2.sub.α and PGE2 |
DE2719901A1 (en) * | 1976-05-04 | 1977-11-24 | Upjohn Co | PGE AND 11-DEOXY-PGE COMPOUNDS WITH A METHYLENE GROUP ON THE C-9 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3864387A (en) * | 1973-05-21 | 1975-02-04 | Upjohn Co | 5-Oxa phenyl-and phenoxy-substituted prostaglandin F{HD 1{301 {0 {B analogs |
US4045449A (en) * | 1975-06-23 | 1977-08-30 | The Upjohn Company | PG-type 1,15-lactones |
-
1980
- 1980-08-06 US US06/175,467 patent/US4289785A/en not_active Expired - Lifetime
-
1981
- 1981-07-30 JP JP56118584A patent/JPS5754119A/ja active Pending
- 1981-08-05 DE DE8181303564T patent/DE3161182D1/en not_active Expired
- 1981-08-05 EP EP81303564A patent/EP0045661B1/en not_active Expired
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3978229A (en) * | 1974-04-11 | 1976-08-31 | Ono Pharmaceutical Co., Ltd. | Synergistic composition comprising PGF2.sub.α and PGE2 |
DE2719901A1 (en) * | 1976-05-04 | 1977-11-24 | Upjohn Co | PGE AND 11-DEOXY-PGE COMPOUNDS WITH A METHYLENE GROUP ON THE C-9 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0097439A2 (en) * | 1982-06-18 | 1984-01-04 | The Upjohn Company | A crystalline prostaglandin salt |
EP0097439A3 (en) * | 1982-06-18 | 1984-10-31 | The Upjohn Company | A crystalline prostaglandin salt |
Also Published As
Publication number | Publication date |
---|---|
DE3161182D1 (en) | 1983-11-17 |
US4289785A (en) | 1981-09-15 |
EP0045661B1 (en) | 1983-10-12 |
JPS5754119A (en) | 1982-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4311707A (en) | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions | |
EP0299914B1 (en) | 9-halogen (z) prostaglandin derivatives, process for their production and their use as medicines | |
AU2005294269B2 (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
EP0045661B1 (en) | Pharmaceutical compositions comprising prostaglandins | |
US3882241A (en) | Use of prostaglandins E and F for prevention of pregnancy in humans | |
KR20030016418A (en) | Composition for treatment of ocular hypertension and glaucoma | |
Dajani et al. | Influence of the position of the side chain hydroxy group on the gastric antisecretory and antiulcer actions of E1 prostaglandin analogs | |
US4289761A (en) | Combination of 5-oxa-17-phenyl-PGF1 α's estrogenic compounds for menses induction | |
US3899587A (en) | Use of prostaglandins E and F for abortion | |
US4005221A (en) | Use of prostaglandins to induce menstruation | |
Bergström et al. | The prostaglandins and human reproduction | |
DE69112080T2 (en) | 2-DECARBOXYL-2-ALKOXYALKYL-PROSTAGLANDINE AS AN EYEBALL PRESSURE-LOWING AGENT. | |
US4089951A (en) | Oestrus or menstrual regulation | |
EP1159965A2 (en) | Method of preventing or inhibiting fertilization | |
CH632743A5 (en) | METHOD FOR PRODUCING NEW PROSTAGLANDIN ANALOGS WITH A 4.5 DOUBLE BINDING. | |
US4904648A (en) | Pharmaceutical preparations for induction of labor and for contraceptive use | |
CH624100A5 (en) | ||
Critser et al. | Effect of indomethacin on the interestrous interval of intact and hysterectomized pseudopregnant mice | |
Csapo | Pregnancy termination in the rat “model” by a synthetic prostaglandin analogue ICI 81008 | |
US3778506A (en) | Use of prostaglandins to induce medical abortion | |
KR20000068996A (en) | Cervical Maturing Agent | |
AU601733B2 (en) | A method for antagonizing the action of progesterone by administering an effective amount of 17 -ethynyl- 17 -acetoxy- 5 -androst- 2 -ene | |
Elger et al. | Pharmacological aspects of early pregnancy and contraception | |
Wilks | Inhibition of the monkey corpus luteum with 15-methyl prostaglandins | |
WO1992013836A1 (en) | 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB IT NL SE |
|
17P | Request for examination filed |
Effective date: 19820713 |
|
ITF | It: translation for a ep patent filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB IT LI NL SE |
|
ET | Fr: translation filed | ||
REF | Corresponds to: |
Ref document number: 3161182 Country of ref document: DE Date of ref document: 19831117 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19840823 Year of fee payment: 4 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19840930 Year of fee payment: 4 Ref country code: BE Payment date: 19840930 Year of fee payment: 4 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19841016 Year of fee payment: 4 |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19841017 Year of fee payment: 4 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19860831 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19870806 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19870831 Ref country code: CH Effective date: 19870831 |
|
BERE | Be: lapsed |
Owner name: THE UPJOHN CY Effective date: 19870831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19880301 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19880429 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19880503 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19881118 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19890831 |
|
EUG | Se: european patent has lapsed |
Ref document number: 81303564.9 Effective date: 19880711 |